Other relevant platforms currently in development include a split, universal, and programmable (SUPRA) CAR system, which is designed to improve specificity and controllability,365 and the RevCAR-T platform, which employs an “AND” logic gate to target CD33 and CD123 in a versatile manner.366 In this context, the incorporation of the “OR” or “AND” logic gate strategies could also prove beneficial in reducing off-tumor side effects, as the tumor with both antigens will be selectively eliminated compared with tumors with a single antigen.367–370. Here, CD33 is linked to neoplasm.